首页> 外文期刊>Scientific reports. >An Evaluation of the Results of the Steroid and Non-steroidal Anti-inflammatory Drug Treatments in Subacute Thyroiditis in relation to Persistent Hypothyroidism and Recurrence
【24h】

An Evaluation of the Results of the Steroid and Non-steroidal Anti-inflammatory Drug Treatments in Subacute Thyroiditis in relation to Persistent Hypothyroidism and Recurrence

机译:评估亚急性甲状腺炎的类固醇和非甾体类抗炎药物治疗的结果与持续的甲状腺功能亢进和复发相关

获取原文
           

摘要

Subacute thyroiditis (SAT) is an inflammatory thyroid disease. The main purpose of the treatment is to relieve pain and control the inflammatory process. The aim of the present study was to evaluate the therapeutic effects of steroid and non-steroidal anti-inflammatory drugs (NSAIDs) in SAT. Initial laboratory data, treatment response, and long-term results of 295 SAT patients treated with ibuprofen or methylprednisolone were evaluated. After the exclusion of 78 patients, evaluation was made of 126 patients treated with 1800 mg ibuprofen and 91 patients treated with 48?mg methylprednisolone. In 59.5% of 126 patients treated with ibuprofen, there was no adequate clinical response at the first control visit. In 54% of patients, the treatment was changed to steroids in mean 9.5 days. Symptomatic remission was achieved within two weeks in all patients treated with methylprednisolone. The total recurrence rate was 19.8%, and recurrences were observed more frequently in patients receiving only steroid therapy than in patients treated with NSAID only (23% vs. 10.5% p:0.04). Persistent hypothyroidism developed in 22.8% of patients treated only with ibuprofen and in 6.6% of patients treated with methylprednisolone only. Treatment with only ibuprofen (p:0.039) and positive thyroid peroxidase antibody (anti-TPO) (p:0.029) were determined as the main risk factors for permanent hypothyroidism. NSAID treatment is not as effective as steroid treatment in early clinical remission. Steroid treatment was detected as a protective factor against permanent hypothyroidism. Therefore, steroid therapy may be considered especially in anti-TPO positive SAT patients and patients with high-level acute phase reactants.
机译:亚急性甲状腺炎(SAT)是一种炎症甲状腺疾病。治疗的主要目的是缓解疼痛并控制炎症过程。本研究的目的是评估类固醇和非甾体类抗炎药(NSAID)在SAT中的治疗效果。评估初始实验室数据,治疗反应和使用布洛芬或甲基新甲醇治疗的295款患者的长期结果。排除78例患者后,评价由126名患者用1800毫克布洛芬治疗,91例患者治疗48毫克甲基己酮醇。在59.5%的126名患者中治疗布洛芬治疗的126名患者中,在第一次对照访问中没有足够的临床反应。在54%的患者中,将治疗改为平均9.5天的类固醇。在用甲基己酮酮治疗的所有患者的两周内实现症状缓解。总复发率为19.8%,仅在仅接受类固醇疗法的患者中更频繁地观察到复发,而不是用NSAID处理的患者(23%对10.5%P:0.04)。持续的甲状腺功能减退症,22.8%的患者仅适用于布洛芬治疗,6.6%的患者仅含有甲基己酮酮治疗。仅使用布洛芬(P:0.039)和阳性甲状腺过氧化物酶抗体(抗TPO)(P:0.029)进行治疗作为永久性甲状腺功能亢进的主要风险因素。 NSAID治疗在早期临床缓解中没有与类固醇治疗有效。针对永久性甲状腺功能亢进的保护剂检测到类固醇治疗。因此,类固醇疗法可能被认为特别是在抗TPO阳性SAT患者和高水平急性相反应物患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号